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Dr Abbas Ardehali (Pacific Palisades, Calif). First, I want to com-
pliment Ms Hoercher for an excellent presentation, and I also want
to thank the authors for forwarding the manuscript to me several
days in advance of this meeting.The Journal of ThorThis is a timely study that investigates the outcome of 100 status
2 patients who are removed from the transplant list because of med-
ical improvement. The strength of this article is the long-term fol-
low-up for 10 years. There were 3 major findings. First, the risk
of return of heart failure or sudden cardiac death was about 3% to
5% per year. Second, survival of this cohort was 93% at 1 year
but decreased precipitously at 5 years to 63% and at 10 years to
35%. Third, when compared with a contemporaneous cohort of
status 2 patients who underwent transplantation, the early survival
of the delisted patients was better, but the survival curves crossed
at 18 months. The status 2 patients who underwent transplantation
had a better survival at 5 and 10 years.
This report contains some good news and some bad news. The
good news is that the highly selected patients who were function-
ally improved can be removed from the waiting list safely, and
for the most part, they do okay in the short term. The bad
news is that most of these patients do poorly in the long term
and can still benefit from heart transplantation, which brings me
to 3 questions.
First, given these findings, how have you modified your ap-
proach to delisting patients, what are your protocols for monitoring
the delisted patients, and at what frequency and at which center are
they delisted?
Ms Hoercher. First, I would like to say that we are listing far
fewer patients now than even 10 years ago. This is indeed a reflection
of the expanded options available both medically and surgically.
Based on these findings, we monitor patients who are listed much
more closely and restage them every 6 months. For patients who
are listed as status 2 and do show signs of medical improvement,
we initially change them to status 7 before removing them from
the list completely. This encourages them to return to see us every
3 to 6 months, at which time we repeat their metabolic stress tests,
right heart catheterizations, echocardiographic analyses, and labora-
tory work-ups. Therefore, I would say that the findings of this study
had a major effect on the way we care for this cohort of patients.
De Ardehali. So all the inactivated patients are brought back to
Cleveland Clinic.
Ms Hoercher. That is correct. One of the key findings was the
loss of follow-up for patients we removed over the past 20 years.
We believe that if they had been followed by a heart failure specialist
using evidence-based guidelines, this could have made a big differ-
ence in survival. Of course, the sobering finding of the high preva-
lence of sudden cardiac death in this group, coupled with such a low
ICD use rate, has changed our practice in this area as well. All pa-
tients whomeet the guidelines, whether they are delisted for medical
improvement or status 2 patients waiting at home, receive ICDs.
In addition, many are now having ICDs combined with cardiac
resynchronization therapy.
Dr Ardehali. So your recommendation is to bring the patients
back to the transplantation center, have them followed by the heart
failure specialist at the transplantation center, and treat them accord-
ing to the guidelines of the transplantation center.
Ms Hoercher. That is correct.
Dr Ardehali. Second, several studies have shown that the sur-
vival of status 2 patients undergoing heart transplantation is similar
to that of those remaining on the waiting list, at least for the short
term, maybe 1 to 3 years. As a result, some authorities in the heart
transplantation community have suggested that it is time foracic and Cardiovascular Surgery c Volume 135, Number 5 1165
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with optimized medical therapy in status 2 patients. Given your find-
ings, do you think such a study is rational, or do you think we should
just look at the Scientific Registry of Transplant Recipients data-
base, maybe at 5 or 10 years out?
Ms Hoercher. I do not think we should be looking at data from
the Scientific Registry of Transplant Recipients at 5 and 10 years un-
less the data collected become much more robust. For example, we
do not know whether patients who are listed as status 2 in the Scien-
tific Registry of Transplant Recipients database have ICDs, nor do
we know their medical therapy, and therefore I do not think that
these data would answer the question of transplantation versus med-
ical therapy.
As far as the other studies you reference, I think we need to see
what their results look like in 5 years before calling for a randomized
trial.
DrArdehali. Finally, as you know, the thoracic organ committee
of UNOS is now considering a new heart allocation system, a system
that incorporates thewait list mortality versus the posttransplantation
1-year survival, which is very similar to the lung allocation score.
Given the findings of the study, is arbitrary 1-year survival, which
has been the benchmark for the lung allocation score and continues
to be the foundation for the allocation system now, valid? Is it ratio-
nal, or should we be looking at the 5-year survival of heart transplant
recipients?
Again, congratulations on an important study and a good presen-
tation.
Ms Hoercher. Thank you. Arbitrary 1-year transplantation sur-
vival is not a rational criterion when making a decision regarding
heart allocation for transplantation. A better guide would be an abil-
ity to determine the difference between expected outcomes with and
without transplantation. I think that once again, you need to balance
the risks and benefits. Certainly, looking at 1-year survival is not
enough; we need to look at 5-year survival as well. But I also think
that we are so focused on survival in this country that we often forget
to consider quality of life. All of us see our patients alive at 18 to 20
years after transplantation, but I see my patients missing lower ex-
tremities, receiving chronic dialysis, and battling cancer, to name
just a few posttransplantation morbidities. Survival alone is not
enough, which is why I think you need to defer transplantation for
your stable status 2 patients as long as possible.
Dr Joseph Cleveland (Denver, Colo). That was a very nice pre-
sentation, and as always, data from Cleveland Clinic have helped
guide a lot of things.
I have 2 questions. First, do you think status 2 patients are equiv-
alent? In other words, one of the things that we wrestle with in1166 The Journal of Thoracic and Cardiovascular Surgery c MColorado is what defines a status 2 patient. I would probably venture
that a status 2 patient in Cleveland might look different than a status
2 patient in Denver, who might look different than a status 2 patient
in Los Angeles. Some of it has to do with how quickly organs are
offered, for example.
Second, what do you think the effect of ventricular assist device
therapymight play in this, particularly with the more recent encourag-
ing reports with destination therapy. Could this then again be, if you
will, with newer-generation devices, selected patients now having sur-
vival at 3 and 5 years of perhaps 70% in centers and other places these
patients can go, because I think the sobering part of your presentation
is what happens to these patients long term. I would agree that having
them followed in a center of heart failure transplantation excellence is
part of it and that this might also be a place where destination therapy
might play a role. I would be curious to hear your thoughts.
Ms Hoercher. I agree with you that a status 2 patient at Cleve-
land Clinic might not be the same as a status 2 patient elsewhere.
That is why UNOS needs to start collecting data on medical therapy,
whether patients have CRT, and whether they have ICDs. I also
think that our patients who were delisted for medical improvement
might have been a sicker group than patients elsewhere.
Your second question was about the role of destination therapy.
I do not believe that there is a role for mechanical support in status
2 patients. Although there is increasing evidence for left ventricular
assist devices earlier in the disease course and before the develop-
ment of end-organ failure, at this time, patients who require inotro-
pic support appear to derive the greatest benefit. It remains to be
seen whether those less severely ill patients not receiving inotropic
support, the status 2 patients, would gain a survival benefit from left
ventricular assist device therapy over that of optimal medical ther-
apy.
Dr John Benfield (Los Angeles, Calif). This is a very important
and thought-provoking paper. Listing, delisting, and selection of pa-
tients for transplantation is an awesome responsibility, and we must
acknowledge that we are not always right. What are your thoughts
about the priority on the transplant list that should be afforded to
or given to delisted patients whose status changes such that they
then again become candidates for transplantation?
Ms Hoercher. That is an excellent question. As a result of this
study, I am wondering whether UNOS should split status 2 into
2a and 2b. Then instead of delisting patients, they could be listed
as 2b, recognizing that such patients would not undergo transplan-
tation for a long time. Again, a key finding of this study is the impor-
tance of close monitoring of these patients. By keeping a patient on
the UNOS list, both the patient and the transplantation center would
likely be more compliant with follow-up.ay 2008
